Literature DB >> 8280345

Naltrexone-buprenorphine interactions: effects on cocaine self-administration.

N K Mello1, S E Lukas, J H Mendelson, J Drieze.   

Abstract

An opioid mixed agonist-antagonist analgesic, buprenorphine, significantly reduces cocaine self-administration by rhesus monkeys, but the relative contribution of buprenorphine's agonist and antagonist properties to this effect is unclear. This study examined the effects of concurrent treatment with naltrexone, a long-acting mu opioid antagonist, on buprenorphine's effects on cocaine and food self-administration by five rhesus monkeys. Cocaine (0.5 mg/kg per injection) and food self-administration (1 gm banana pellet) were maintained on a second order fixed ratio 4 (FR4) variable ratio (VR) 16:S schedule of reinforcement. Buprenorphine treatment alone (0.40 mg/kg/day) and in combination with ascending doses of naltrexone (0.05, 0.10, 0.20, and 0.40 mg/kg/day) was compared with naltrexone alone (0.40 mg/kg/day) and saline control treatment. Naltrexone was administered simultaneously or 20 minutes before buprenorphine administration. Each treatment condition was in effect for 10 days. Buprenorphine alone significantly reduced cocaine self-administration by an average of 53% in comparison to the saline treatment baseline (p < .01). When saline was substituted for buprenorphine, each monkey rapidly returned to its prebuprenorphine level of cocaine self-administration. Food self-administration in all conditions was equivalent to or significantly higher (p < .05) than food-maintained responding during the saline baseline. When buprenorphine and naltrexone were administered simultaneously, naltrexone significantly attenuated buprenorphine's suppressive effects on cocaine self-administration (p < .05 to .01). When naltrexone was administered 20 minutes before buprenorphine, there was a significant naltrexone dose-dependent (p < .01) decrease in buprenorphine's reduction of cocaine self-administration in comparison to the initial saline baseline. These data suggest that naltrexone antagonizes the partial mu agonist component of buprenorphine, which may be important for buprenorphine's effects on cocaine self-administration. Moreover, the addition of an opioid antagonist to reduce illicit diversion of buprenorphine might also compromise its effectiveness for treatment of dual dependence on cocaine and opiates.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280345     DOI: 10.1038/npp.1993.57

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  11 in total

1.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

2.  Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Authors:  Marsida Kallupi; Qianwei Shen; Giordano de Guglielmo; Dennis Yasuda; V Blair Journigan; Nurulain T Zaveri; Roberto Ciccocioppo
Journal:  Addict Biol       Date:  2017-06-21       Impact factor: 4.280

3.  EVALUATION OF DRUG ABUSE TREATMENT MEDICATIONS: CONCORDANCE BETWEEN CLINICAL AND PRECLINICAL STUDIES.

Authors:  N K Mello
Journal:  NIDA Res Monogr       Date:  2005-05

4.  Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice.

Authors:  G C Sartor; S K Powell; H J Wiedner; C Wahlestedt; S P Brothers
Journal:  Brain Res       Date:  2015-12-03       Impact factor: 3.252

5.  A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence.

Authors:  Sunmee Wee; Leandro F Vendruscolo; Kaushik K Misra; Joel E Schlosburg; George F Koob
Journal:  Sci Transl Med       Date:  2012-08-08       Impact factor: 17.956

6.  Cebranopadol Blocks the Escalation of Cocaine Intake and Conditioned Reinstatement of Cocaine Seeking in Rats.

Authors:  Giordano de Guglielmo; Alessandra Matzeu; Jenni Kononoff; Julia Mattioni; Rémi Martin-Fardon; Olivier George
Journal:  J Pharmacol Exp Ther       Date:  2017-06-23       Impact factor: 4.030

Review 7.  The kappa-opiate receptor impacts the pathophysiology and behavior of substance use.

Authors:  David Mysels; Maria A Sullivan
Journal:  Am J Addict       Date:  2009 Jul-Aug

8.  Buprenorphine + naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study.

Authors:  Walter Ling; Maureen P Hillhouse; Andrew J Saxon; Larissa J Mooney; Christie M Thomas; Alfonso Ang; Abigail G Matthews; Albert Hasson; Jeffrey Annon; Steve Sparenborg; David S Liu; Jennifer McCormack; Sarah Church; William Swafford; Karen Drexler; Carolyn Schuman; Stephen Ross; Katharina Wiest; P Todd Korthuis; William Lawson; Gregory S Brigham; Patricia C Knox; Michael Dawes; John Rotrosen
Journal:  Addiction       Date:  2016-04-21       Impact factor: 6.526

Review 9.  Evaluation of the "Pipeline" for Development of Medications for Cocaine Use Disorder: A Review of Translational Preclinical, Human Laboratory, and Clinical Trial Research.

Authors:  Paul W Czoty; William W Stoops; Craig R Rush
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

Review 10.  The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Authors:  Jeffrey M Witkin; Michael A Statnick; Linda M Rorick-Kehn; John E Pintar; Michael Ansonoff; Yanyun Chen; R Craig Tucker; Roberto Ciccocioppo
Journal:  Pharmacol Ther       Date:  2013-11-01       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.